Kidney cancer medicines

The following table lists the status of individual kidney cancer medicines in England, Wales, Scotland, and Northern Ireland, and whether they are available within the NHS in each individual country.

Download and print a pdf of the table here: Access to kidney cancer medicines in the UK – October 2022

Access to kidney cancer medicines in the UK – June 2022

Trade name

Manufacturer

Generic name How it works Indication Availability
 First-line treatments
Keytruda

MSD

Pembrolizumab Immunotherapy: anti-PD1 checkpoint inhibitor infusion Adjuvant treatment for locally advanced moderate to high risk RCC Available on the NHS
Kisplyx plus Keytruda

Eisai/MSD

 

Lenvatinib in combination with pembrolizumab Targeted therapy plus immunotherapy: VEGF tyrosine kinase inhibitor (TKI) plus anti-PD1 checkpoint inhibitor

Infusion plus oral medication

First-line treatment for advanced RCC Restricted access under a Patient Access Scheme (PAS) in Scotland. Not available on the NHS in England and Wales.
Cabometyx plus Opdivo

Ipsen/BMS

 

Cabozantinib in combination with nivolumab Targeted therapy plus immunotherapy: VEGF tyrosine kinase inhibitor (TKI) plus anti-PD1 checkpoint inhibitor

Oral medication plus infusion

First-line treatment for advanced RCC Restricted access under a Patient Access Scheme (PAS) in Scotland. Not available on the NHS in England and Wales
Bavencio plus Inlyta

Merck/Pfizer

Avelumab in combination with axitinib Immunotherapy plus targeted therapy: Anti-PD-L1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI)

Infusion plus oral medication

First-line treatment for advanced/metastatic RCC Available via the Cancer Drugs Fund (CDF) for patients in England and Wales. Available on the NHS in Scotland
Keytruda plus Inlyta

MSD/Pfizer

Pembrolizumab in combination with axitinib Immunotherapy plus targeted therapy: Anti-PD1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI)

Infusion plus oral medication

First-line treatment for advanced RCC Available on the NHS in Scotland under a Patient Access Scheme (PAS). Not available on the NHS in England and Wales
Opdivo plus Yervoy

BMS

Nivolumab in combination with ipilimumab Immunotherapy: Anti-PD1 checkpoint inhibitor plus anti-CTLA4 inhibitor

Infusion

First-line treatment for intermediate and poor risk advanced RCC Available on the NHS
Sutent

Pfizer

Sunitinib Targeted therapy: VEGF tyrosine kinase inhibitor (TKI)

Oral medication

First-line treatment for metastatic RCC Available on the NHS
Votrient

Novartis

Pazopanib Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication First-line treatment for metastatic RCC Available on the NHS
Cabometyx

Ipsen

Cabozantinib Targeted therapy: VEGF tyrosine kinase inhibitor (TKI)

Oral medication

First-line treatment for locally advanced/metastatic RCC Available on the NHS
Fotivda

Aveo/Eusa

Tivozanib Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication First-line treatment for metastatic RCC Available on the NHS
 Second-line treatments
Kisplyx plus Afinitor

Eisai, Novartis

Lenvatinib in combination with everolimus Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) plus mTOR inhibitor

Oral medication

Second-line treatment for advanced RCC Available on the NHS
Inlyta

Pfizer

Axitinib Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication Second-line treatment for advanced RCC Available on the NHS
 Second line and beyond treatments
Opdivo

BMS

 

Nivolumab Immunotherapy: Anti-PD1 checkpoint inhibitor Second/third-line treatment for advanced/metastatic RCC Available on the NHS
Cabometyx

Ipsen

Cabozantinib Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication Second/third-line treatment for advanced RCC after VEGF-TKI treatment Available on the NHS
Afinitor

Novartis

Everolimus Targeted therapy: mTOR inhibitor

Oral medication

Second/third-line treatment for advanced RCC Available on the NHS in England, Scotland and Wales
 Other treatments for advanced kidney cancer
Proleukin

Clinigen

Interleukin 2 (IL 2) Immunotherapy: Cytokine

Infusion

Advanced/metastatic RCC Available to pre-selected patients only at specialist research sites (Christie Hospital, Manchester). Not funded by the NHS
Torisel

Pfizer

Temsirolimus Targeted therapy: mTOR inhibitor

Oral medication

 

First-line treatment for advanced RCC of poor prognosis Not routinely available on the NHS

Access via individual funding request*

Avastin

Roche

Bevacizumab Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Infusion First-line treatment for advanced/metastatic RCC in combination with interferon alpha Not routinely available on the NHS

Access via individual funding request*

Nexavar

Bayer

Sorafenib Targeted therapy: VEGF tyrosine kinase inhibitor (TKI)

Oral medication

First/second-line treatment for advanced/metastatic RCC Not routinely available on the NHS

Access via individual funding request*

Tecentriq plus

Avastin

Roche

Atezolizumab in combination with bevacizumab Immunotherapy plus targeted therapy: Anti-PD-L1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI)

Infusion

First-line treatment for locally advanced/metastatic RCC Appraisal suspended
Xgeva

Amgen

Denosumab Immunotherapy: RANK ligand inhibitor

Injection

Cancer that has spread to the bones as an alternative to bisphosphonates Available on the NHS

Please see our clinical trials database for a complete list of all clinical trials for kidney cancer in the UK.

*Individual funding requests may be submitted via the following route:

Please visit Access to medicines not available on the NHS for more information about individual funding requests.

The following paper describes the special case for access to interleukin 2 (IL 2), which is only available at the Christie Hospital in Manchester and not routinely available on the NHS. The paper describes the experience of the Christie Hospital with IL 2 over a 10-year period and how careful selection of patients gives excellent results: High dose IL-2

The European Society of Medical Oncology (ESMO) has published a leaflet describing immunotherapy-related side effects to help patients, family, friends and carers to better understand them. It contains information on the most common side effects associated with modern immunotherapies (checkpoint inhibitors) and how your oncologist and healthcare team will manage them. It also gives a few strategies that you can use to help minimise these side effects. Read the leaflet here: ESMO Patient Guide on Immunotherapy Side Effects